| Trial ID: | L0185 |
| Source ID: | NCT01913470
|
| Associated Drug: |
Losartan
|
| Title: |
Study of Losartan in the Treatment of NAFLD in Children
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
Has Results
|
| Results: |
https://ClinicalTrials.gov/show/NCT01913470/results
|
| Conditions: |
NAFLD
|
| Interventions: |
Drug: Losartan
|
| Outcome Measures: |
Change in Alanine Aminotransferase (ALT) From Baseline to End of Treatment (8 Weeks of Treatment)|Change in Cholesterol Levels From Baseline to End of Treatment (8 Weeks of Treatment)|Change in Triglyceride Levels From Baseline to End of Treatment (8 Weeks of Treatment)|Change in Fatty Acid Levels From Baseline to End of Treatment (8 Weeks of Treatment)|Changes in Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR) Between Baseline and End of Treatment (8 Weeks of Treatment)|Changes in Plasminogen Activator Inhibitor-1 (PAI-1) Concentrations Between Baseline and End of Treatment
|
| Sponsor/Collaborators: |
Miriam Vos, MD|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Children's Healthcare of Atlanta|Emory University
|
| Gender: |
All
|
| Age: |
11 Years to 19 Years ?? (Child, Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
12
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
July 2013
|
| Completion Date: |
December 2015
|
| Results First Posted: |
May 15, 2017
|
| Last Update Posted: |
May 15, 2017
|
| Locations: |
Emory University / Children's Healthcare of Atlanta, Atlanta, Georgia, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT01913470
|
